About: Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement
Creator	Amirfakhryan, Hamideh Fatemeh, Hamideh, Amirfakhryan Safari, Fatemeh
Source	Elsevier; Medline; PMC
abstract	Since the new coronavirus SARS (SARS-CoV2) has emerged from china, the infection (COVID-19) has affected many countries and led to many deaths worldwide. Like SARS-CoV, ACE2 as a functional receptor for SARS-CoV2 is essential for virus to entry to the cell. ACE2 is a part of RAS which is expressed in several organs that opposes the AngII functions by converting Ang II to Ang (1-7), the one with vasodilation effects. The death rate of COVID-19 is estimated about 3.4%, however, some comorbid conditions like underlying cardiovascular disease, hypertension, and diabetes increase the risk of mortality. In addition, cardiovascular involvement by SARS-CoV2 could be direct through either ACE2 receptors which are expressed tremendously in heart, or by the surge of different cytokines or by ARDS-induced hypoxia. Traditional risk factors could aggravate the process of COVID-19 infection that urges the triage of these high risk patients for SARS-CoV2. Currently, there is no effective, proven treatment or vaccination for COVID-19, but many investigators are struggling to find a treatment strategy as soon as possible. Some potential medications like chloroquine by itself or in combination with azithromycin, and some protease inhibitors used for the treatment of COVID-19 have cardiovascular adverse effects that should be kept in mind in order to close monitor of the patients receiving these medications.
has issue date	2020-06-06(xsd:dateTime)
bibo:doi	10.1016/j.hjc.2020.05.007
bibo:pmid	32522617
has license	no-cc
sha1sum (hex)	bc8fbc8363cef011b89fa8c7cb1acbd67078c7c1
schema:url	https://doi.org/10.1016/j.hjc.2020.05.007
resource representing a document's title	Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement
has PubMed Central identifier	PMC7275139
has PubMed identifier	32522617
schema:publication	Hellenic J Cardiol
resource representing a document's body	covid:bc8fbc8363cef011b89fa8c7cb1acbd67078c7c1#body_text
is schema:about of	named entity 'functions' named entity 'expressed' named entity 'combination' named entity 'comorbid' named entity 'heart' named entity 'Pathogenesis' named entity 'PART OF' named entity 'RECEIVING' named entity 'ENTRY' named entity 'VIRUS' named entity '3.4' named entity 'IS A' named entity 'RISK FACTORS' named entity 'MONITOR' named entity 'PROTEASE INHIBITORS' named entity 'INDUCED' named entity 'ANGII' named entity 'RISK OF' named entity 'CARDIOVASCULAR' named entity 'CYTOKINES' named entity 'TRADITIONAL' named entity 'ADVERSE EFFECTS' named entity 'COMBINATION' named entity 'adverse effects' named entity 'ANG' named entity 'receptors' named entity 'organs' named entity 'urges' named entity 'infection' named entity 'receiving' named entity 'china' named entity 'infection' named entity 'diabetes' named entity 'receptor' named entity 'azithromycin' named entity 'SARS-CoV2' named entity 'vaccination' named entity 'SARS-CoV2' named entity 'ACE2' named entity 'SARS-CoV2' named entity 'COVID-19' named entity 'adverse effects' named entity 'SARS-CoV2' named entity 'Pathogenesis' named entity 'cardiovascular' named entity 'infection' named entity 'SARS-CoV2' named entity 'COVID-19' named entity 'ACE inhibitors' named entity 'ACE' named entity 'ACE2' named entity 'metallopeptidase' named entity 'SARS-CoV2' named entity 'antibody' named entity 'ammonium chloride' named entity 'ICU' named entity 'heat rate' named entity 'genome' named entity 'SARS-CoV2' named entity 'remdesivir' named entity 'CDC' named entity 'cytokine storm syndrome' named entity 'SARS-CoV' named entity 'ACE' named entity 'myocarditis' named entity 'diabetes' named entity 'protein' named entity 'troponin' named entity 'syncope' named entity 'SARS-CoV2' named entity 'clopidogrel' named entity 'SARS-CoV' named entity 'cardiac arrhythmia' named entity 'NHC' named entity 'viral RNA' named entity 'Hydroxychloroquine' named entity 'obesity' named entity 'infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software